Insmed, Inc. (NASDAQ:INSM)’s share price was up 6.4% during mid-day trading on Thursday . The company traded as high as $31.25 and last traded at $31.19. Approximately 562,509 shares were traded during mid-day trading, a decline of 18% from the average daily volume of 685,514 shares. The stock had previously closed at $29.32.

A number of equities analysts have recently issued reports on INSM shares. Stifel Nicolaus restated a “buy” rating and issued a $43.00 price objective (up previously from $27.00) on shares of Insmed in a research note on Wednesday, September 6th. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Insmed in a research note on Monday, November 6th. Zacks Investment Research cut shares of Insmed from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Cowen restated an “outperform” rating and issued a $54.00 price objective on shares of Insmed in a research note on Wednesday, September 6th. Finally, BidaskClub cut shares of Insmed from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Insmed has a consensus rating of “Hold” and an average price target of $34.50.

The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13.

In related news, Director Donald J. Hayden, Jr. sold 45,000 shares of the stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $29.67, for a total transaction of $1,335,150.00. Following the completion of the sale, the director now owns 71,131 shares in the company, valued at approximately $2,110,456.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Melvin Md Sharoky sold 50,000 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $27.37, for a total transaction of $1,368,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock valued at $3,191,150 in the last quarter. 5.10% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in INSM. Parametric Portfolio Associates LLC increased its position in shares of Insmed by 39.2% during the 1st quarter. Parametric Portfolio Associates LLC now owns 14,417 shares of the biopharmaceutical company’s stock worth $252,000 after purchasing an additional 4,063 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Insmed by 4.8% during the 1st quarter. Vanguard Group Inc. now owns 3,781,483 shares of the biopharmaceutical company’s stock worth $66,214,000 after purchasing an additional 173,532 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Insmed by 6.9% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 283,167 shares of the biopharmaceutical company’s stock worth $4,959,000 after purchasing an additional 18,331 shares in the last quarter. Bank of America Corp DE increased its position in shares of Insmed by 191.4% during the 1st quarter. Bank of America Corp DE now owns 33,804 shares of the biopharmaceutical company’s stock worth $592,000 after purchasing an additional 22,204 shares in the last quarter. Finally, State Street Corp increased its position in shares of Insmed by 4.8% during the 1st quarter. State Street Corp now owns 1,499,611 shares of the biopharmaceutical company’s stock worth $26,259,000 after purchasing an additional 68,319 shares in the last quarter. Institutional investors and hedge funds own 95.27% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2017/11/30/insmed-insm-shares-up-6-4.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.